Department of Orthopaedic Surgery, University of California Los Angeles, Los Angeles, CA.
Department of Orthopaedic Surgery, The Johns Hopkins University, Baltimore, MD.
J Hand Surg Am. 2023 Sep;48(9):923-930. doi: 10.1016/j.jhsa.2023.02.013. Epub 2023 Apr 7.
Many hand surgeons treat benign bone tumors without referral to orthopedic oncologists. However, there have been considerable advances in medical therapy for some of these tumors, with which hand surgeons may not be as familiar. This review focuses on the mechanism and uses of denosumab in the treatment of benign tumors of bone. Although the hand surgeon may not be directly prescribing this therapy, they are often the only physician treating the patient for these conditions. As such, awareness regarding the use of this therapy in reducing pain, decreasing tumor volume, and treatment of potential lung metastases is critical to those taking on these cases without the support of an orthopedic oncologist. This article aims to familiarize hand surgeons with denosumab to help promote knowledge of this therapeutic option and the potential role of this medication in the treatment of primary bone tumors in the hand.
许多手外科医生在治疗良性骨肿瘤时不向骨科肿瘤学家转诊。然而，一些良性肿瘤的药物治疗已经取得了相当大的进展，而手外科医生可能对此并不熟悉。这篇综述重点介绍了地舒单抗在治疗骨良性肿瘤中的作用机制和用途。尽管手外科医生可能不会直接开这种治疗药物，但他们通常是唯一为这些疾病治疗患者的医生。因此，对于那些在没有骨科肿瘤学家支持的情况下处理这些病例的医生来说，了解这种治疗方法在减轻疼痛、减少肿瘤体积和治疗潜在肺转移方面的作用至关重要。本文旨在使手外科医生熟悉地舒单抗，以帮助推广对手外科医生的了解，以及这种药物在治疗手部原发性骨肿瘤方面的潜在作用。
